FILANA THERAPEUTICS, INC.
paintrials.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Filana Therapeutics shows significant financial deterioration with cash declining from $95.5M to $86.6M in Q1 2026, ongoing substantial losses of $10.3M quarterly, and a current cash burn rate that threatens viability. Despite reduced R&D spending, the company continues burning cash with no revenue generation and declining stockholder equity.
Red Flags Detected (6)
Cash declining $8.9M in single quarter from $95.5M to $86.6M
Net cash used in operations $8.9M in Q1 2026 vs $11.3M in Q1 2025
Accumulated deficit increased to $506.4M from $496.1M
3 more red flags detected
Key Takeaways
Company reduced R&D spending 67% year-over-year ($4.5M vs $13.7M) indicating potential program cuts
G&A expenses reduced 39% year-over-year showing cost management efforts
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.